ArticleThe oncologist2025
Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundLimited data are available on estradiol (E2) levels during fulvestrant treatment in women with hormone receptor-positive breast cancer.
methodsWe measured plasma E2 levels in women receiving fulvestrant using liquid chromatography-tandem mass spectrometry. Patient characteristics and treatment efficacy were assessed in relation to E2 levels. A cutoff of 2.72 pg/mL was used because it defines E2 suppression and postmenopausal status.
resultsA total of 69 women were enrolled, with a median age of 48 years. The median duration of fulvestrant treatment was 11.6 months. The median E2 level across the cohort was 3.60 pg/mL, with considerable interindividual variability (range: 1.11-526.13 pg/mL), and 49 women (71.0%) had E2 levels above 2.72 pg/mL. Eleven women (15.9%) had premenopausal E2 levels (>10 pg/mL). During a median follow-up period of 8.4 months, there was no statistically significant difference in progression-free survival (PFS) between women with E2 levels >2.72 pg/mL and those with E2 levels ≤2.72 pg/mL (P = .391). However, among women who benefited from first- or second-line fulvestrant therapy (PFS > 6 months), those with E2 levels >2.72 pg/mL exhibited significantly poorer PFS compared to those with E2 levels ≤2.72 pg/mL (P = .043).
conclusionsThese findings support the need for E2 monitoring in women receiving fulvestrant therapy to better assess E2 status and its association with treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.